Levetiracetam
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Motor Neuron Disease
Conditions
Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis, Progressive Muscular Atrophy
Trial Timeline
May 1, 2006 → Jun 1, 2008
NCT ID
NCT00324454About Levetiracetam
Levetiracetam is a phase 2 stage product being developed by UCB for Motor Neuron Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00324454. Target conditions include Motor Neuron Disease, Amyotrophic Lateral Sclerosis, Primary Lateral Sclerosis.
What happened to similar drugs?
2 of 18 similar drugs in Motor Neuron Disease were approved
Approved (2) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03340064 | Phase 3 | Completed |
| NCT01618877 | Phase 1 | Completed |
| NCT01407523 | Phase 2 | Completed |
| NCT01398956 | Phase 3 | Completed |
| NCT01292837 | Phase 3 | Completed |
| NCT01063764 | Phase 3 | Completed |
| NCT00505934 | Phase 2 | Completed |
| NCT00627133 | Phase 2 | Withdrawn |
| NCT00535392 | Phase 2 | Completed |
| NCT00376766 | Phase 3 | Terminated |
| NCT00361010 | Pre-clinical | Completed |
| NCT01318408 | Approved | Completed |
| NCT00367432 | Phase 3 | Completed |
| NCT00291655 | Phase 3 | Completed |
| NCT00324454 | Phase 2 | Completed |
| NCT00319605 | Pre-clinical | Completed |
| NCT00307450 | Approved | Completed |
| NCT00279617 | Phase 3 | Completed |
| NCT00325182 | Approved | Completed |
| NCT00252954 | Approved | Completed |
Competing Products
20 competing products in Motor Neuron Disease